Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vir Biotechnology Inc
(NQ:
VIR
)
8.620
-0.150 (-1.71%)
Streaming Delayed Price
Updated: 12:32 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
149,035
Open
8.820
Bid (Size)
8.620 (1)
Ask (Size)
8.630 (7)
Prev. Close
8.770
Today's Range
8.540 - 8.845
52wk Range
7.610 - 13.27
Shares Outstanding
133,976,538
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Breaking Down Vir Biotechnology: 6 Analysts Share Their Views
August 02, 2024
Via
Benzinga
Performance
YTD
-17.98%
-17.98%
1 Month
-19.44%
-19.44%
3 Month
-19.66%
-19.66%
6 Month
-27.56%
-27.56%
1 Year
-34.25%
-34.25%
More News
Read More
VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024
August 01, 2024
Via
InvestorPlace
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Evaluating Vir Biotechnology: Insights From 5 Financial Analysts
May 24, 2024
Via
Benzinga
Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark
July 26, 2024
Via
Investor's Business Daily
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
July 04, 2024
Via
InvestorPlace
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
June 26, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Deep Dive Into Vir Biotechnology Stock: Analyst Perspectives (6 Ratings)
May 07, 2024
Via
Benzinga
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
June 05, 2024
Via
Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 05, 2024
Via
Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
June 05, 2024
Via
Benzinga
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
June 05, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
May 29, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
May 23, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
May 22, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
May 21, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
VIR Stock Earnings: Vir Biotechnology Beats EPS for Q1 2024
May 02, 2024
Via
InvestorPlace
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 02, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
April 30, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
April 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
April 11, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.